EGFR and neoplasm: There is strong evidence in support of this: EGFR is frequently overexpressed in ∼40% of GBMs, its overexpression correlates with a poor prognosis in patients, and early studies using specific anti-EGFR agents have shown efficacy to increase survival in mice xenotransplanted with tumours directly established from patients (Eller et al, 2002).